Denmark's IO Vaccine Biotech Attracts Investor Interest
IO Biotech's Oversubscribed €127m Series B
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.
